These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 31640747)

  • 1. Targeting of prostate-specific membrane antigen for radio-ligand therapy of triple-negative breast cancer.
    Morgenroth A; Tinkir E; Vogg ATJ; Sankaranarayanan RA; Baazaoui F; Mottaghy FM
    Breast Cancer Res; 2019 Oct; 21(1):116. PubMed ID: 31640747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [
    Arbuznikova D; Klotsotyra A; Uhlmann L; Domogalla LC; Steinacker N; Mix M; Niedermann G; Spohn SKB; Freitag MT; Grosu AL; Meyer PT; Gratzke C; Eder M; Zamboglou C; Eder AC
    Theranostics; 2024; 14(6):2560-2572. PubMed ID: 38646643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor.
    Chakraborty S; Chakravarty R; Shetty P; Vimalnath KV; Sen IB; Dash A
    J Labelled Comp Radiopharm; 2016 Jul; 59(9):364-71. PubMed ID: 27264278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel [
    Wang R; Jin W; Luo Y; Hong H; Zhao R; Li L; Yan L; Qiao J; Ploessl K; Zhu L; Kung HF
    Mol Pharm; 2024 Jul; 21(7):3256-3267. PubMed ID: 38856975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Multidose Preparation of a Ready-to-Use
    Chakraborty A; Mitra A; Tawate M; Sahoo S; Lad S; Rakshit S; Gaikwad S; Basu S; Shimpi H; Banerjee S
    Cancer Biother Radiopharm; 2021 Oct; 36(8):682-692. PubMed ID: 34402687
    [No Abstract]   [Full Text] [Related]  

  • 6. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
    Umbricht CA; Benešová M; Schibli R; Müller C
    Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and Evaluation of
    Zhao R; Ploessl K; Zha Z; Choi S; Alexoff D; Zhu L; Kung HF
    Mol Pharm; 2020 Dec; 17(12):4589-4602. PubMed ID: 33108189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.
    Afshar-Oromieh A; Hetzheim H; Kratochwil C; Benesova M; Eder M; Neels OC; Eisenhut M; Kübler W; Holland-Letz T; Giesel FL; Mier W; Kopka K; Haberkorn U
    J Nucl Med; 2015 Nov; 56(11):1697-705. PubMed ID: 26294298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
    Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ
    J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
    Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW
    Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Potential of PSMA as a Vascular Target in TNBC.
    Heesch A; Ortmanns L; Maurer J; Stickeler E; Sahnoun SEM; Mottaghy FM; Morgenroth A
    Cells; 2023 Feb; 12(4):. PubMed ID: 36831218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New PSMA-Targeting Ligands: Transformation from Diagnosis (Ga-68) to Radionuclide Therapy (Lu-177).
    Zha Z; Choi SR; Li L; Zhao R; Ploessl K; Yao X; Alexoff D; Zhu L; Kung HF
    J Med Chem; 2022 Oct; 65(19):13001-13012. PubMed ID: 36103652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
    Baum RP; Kulkarni HR; Schuchardt C; Singh A; Wirtz M; Wiessalla S; Schottelius M; Mueller D; Klette I; Wester HJ
    J Nucl Med; 2016 Jul; 57(7):1006-13. PubMed ID: 26795286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of post-therapy
    Tuncel M; Telli T
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):114-117. PubMed ID: 28750750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancing Treatment Efficacy of
    Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F
    Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
    Benešová M; Umbricht CA; Schibli R; Müller C
    Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prostate-specific membrane antigen holds potential as a vascular target for endogenous radiotherapy with [
    Heesch A; Florea A; Maurer J; Habib P; Werth LS; Hansen T; Stickeler E; Sahnoun SEM; Mottaghy FM; Morgenroth A
    Breast Cancer Res; 2024 Feb; 26(1):30. PubMed ID: 38378689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [PSMA-targeted radioligand therapy in prostate cancer].
    Heck MM; Retz M; Tauber R; Knorr K; Kratochwil C; Eiber M
    Urologe A; 2017 Jan; 56(1):32-39. PubMed ID: 27885457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicentric, single arm, open-label, phase I/II study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer (PRadR).
    Kryza D; Vinceneux A; Bidaux AS; Garin G; Tatu D; Cropet C; Badel JN; Perol D; Giraudet AL
    BMC Cancer; 2024 Feb; 24(1):163. PubMed ID: 38302933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of PSMA and Internalization of an Anti-PSMA mAb in the Vascular Compartment.
    Nguyen DP; Xiong PL; Liu H; Pan S; Leconet W; Navarro V; Guo M; Moy J; Kim S; Ramirez-Fort MK; Batra JS; Bander NH
    Mol Cancer Res; 2016 Nov; 14(11):1045-1053. PubMed ID: 27458033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.